Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Therapeutics for Nipah virus disease: a systematic review to support prioritisation of drug candidates for clinical trials

Chan XHS. et al, (2024), The Lancet Microbe, 101002 - 101002

Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

Horby PW. et al, (2024)

14.1 In Practice: RECOVERY Trial

Horby P. et al, (2024), Principles and Practice of Emergency Research Response

In Practice: RECOVERY Trial

Horby P. et al, (2024), Principles and Practice of Emergency Research Response

Group sequential designs for clinical trials when the maximum sample size is uncertain.

Yarahmadi A. et al, (2024), Stat Med

Presentation and outcomes of Lassa fever in children in Nigeria: a prospective cohort study (LASCOPE).

Duvignaud A. et al, (2024), J Pediatric Infect Dis Soc

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) for hospitalised patients with COVID-19: prospective meta-analysis of randomised trials

Vale C. et al, (2024), Lancet Diabetes & Endocrinology

An open-label, randomized, non-inferiority trial of the efficacy and safety of ciprofloxacin versus an aminoglycoside + ciprofloxacin in the treatment of bubonic plague (IMASOY): study protocol for a randomized control trial-an update to the published protocol.

Randremanana RV. et al, (2024), Trials, 25

Clinical trial results in context: comparison of baseline characteristics and outcomes of 38,510 RECOVERY trial participants versus a reference population of 346,271 people hospitalised with COVID-19 in England

Pessoa-Amorim G. et al, (2024), Trials

Characteristics and outcomes of COVID-19 patients admitted to hospital with and without respiratory symptoms.

Citarella BW. et al, (2024), Heliyon, 10

Molnupiravir or nirmatrelvir-ritonavir versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Horby PW. et al, (2024)

Interpretations of Studies on SARS-CoV-2 Vaccination and Post-acute COVID-19 Sequelae.

Gonçalves BP. et al, (2024), Epidemiology, 35, 368 - 371

High-dose corticosteroid therapy in COVID-19: the RECOVERY trial - Authors' reply.

Peto L. et al, (2024), Lancet, 403, 1339 - 1340

Nipah Virus Therapeutics: A Systematic Review to Support Prioritisation for Clinical Trials

Chan XHS. et al, (2024)

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2024), Lancet Child Adolesc Health, 8, 190 - 200

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None. et al, (2024), Nat Commun, 15

‘Involve those, who are managing these outbreaks’– Identifying barriers and facilitators to the implementation of clinical management guidelines for High-Consequence Infectious Diseases in Uganda

Kabajaasi O. et al, (2024)

Nipah virus disease: what can we do to improve patient care?

Hassan MZ. et al, (2024), Lancet Infectious Diseases

Expanded Access Programme for the use of tecovirimat for the treatment of monkeypox infection: A study protocol for an Expanded Access Programme.

Bourner J. et al, (2024), PLoS One, 19

Mpox: The alarm went off. Have we gone back to sleep?

Olliaro P. et al, (2024), PLoS Negl Trop Dis, 18

Load More

Include forthcoming?